South Korea's Samsung Biologics said it has made an all-cash acquisition offer of Swiss Poly Peptide Group for 1.46 billion Swiss francs (approximately US$1.8 billion); Poly Peptide Group is a professional company focusing on peptide APIs
South Korea's Samsung Biologics said it has made an all-cash acquisition offer of Swiss PolyPeptide Group for 1.46 billion Swiss francs (approximately US$1.8 billion). PolyPeptide Group is a professional company focusing on peptide APIs. Through this acquisition, the company will expand its pipeline in the field of peptide therapeutics to enter the hot weight loss drug market. The South Korean biopharmaceutical company expects to close the deal before the end of the year. PolyPeptide's stock price rose nearly 5.3% at one time.